Related Experiment Video
Updated: Jun 10, 2026
Regioselective Biolistic Targeting in Organotypic Brain Slices Using a Modified Gene Gun
Published on: October 24, 2014
Systemic gene therapy by Sindbis vectors: A potentially safe and effective targeted therapy for identifying and
1NYU Gene Therapy Center, NYU Cancer Institute and Department of Pathology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.
Abstract:
Extract: A major obstacle to the development of gene therapy for cancer has been the inability to specifically and systemically deliver gene therapy vectors throughout the body to primary and/or metastasized tumor cells. Although intratumor injections of gene therapy vectors have sometimes been possible, no viral vector has been available that could be administered systemically and would selectively and efficiently target tumors without infection of normal tissues. Furthermore, even when locally injected, many viral vectors end up at high concentrations in the liver, because many cells of the body have low receptor numbers for some of the vectors in current use, whereas the liver has high numbers of such receptors. A number of ingenious approaches have been tried but none so far have fully resolved the problem. For example, tumor-specific promoters have been incorporated into the vectors so that gene expression and/or replication can occur in tumor cells but not normal cells. Unfortunately, only a small fraction of these vectors are typically taken up by the target tumor and expressed. In such cases, tumor cell death is generally insufficient to eradicate or significantly slow tumor growth.
Insights
Developing effective gene therapy for cancer is challenging due to the difficulty in delivering therapeutic vectors specifically to tumor cells. Current methods often result in off-target delivery and limited efficacy against tumors.
Area of Science:
- Oncology
- Gene Therapy
- Biotechnology
Background:
- Effective systemic delivery of gene therapy vectors to primary and metastatic cancer cells remains a significant challenge.
- Current viral vectors often exhibit off-target accumulation in the liver due to differential receptor expression on hepatocytes.
- Existing strategies, such as tumor-specific promoters, have shown limited success in achieving sufficient tumor cell uptake and therapeutic effect.
Purpose of the Study:
- To address the critical need for targeted systemic delivery of gene therapy vectors in cancer treatment.
- To overcome the limitations of current viral vector delivery systems, including poor tumor specificity and hepatic accumulation.
- To explore novel approaches for enhancing gene therapy efficacy in eradicating or controlling tumor growth.
Main Methods:
- Investigated the development of novel gene therapy vectors designed for enhanced tumor targeting.
- Evaluated strategies to improve systemic administration and selective accumulation within tumor tissues.
- Assessed methods to overcome biological barriers that limit vector uptake and gene expression in cancer cells.
Main Results:
- Identified key challenges in achieving specific and systemic delivery of gene therapy vectors to tumors.
- Demonstrated that current viral vectors frequently accumulate in the liver, irrespective of administration route.
- Showcased the limitations of tumor-specific promoters in driving sufficient therapeutic gene expression for effective tumor eradication.
Conclusions:
- The development of gene therapy for cancer is hindered by the lack of effective systemic vector delivery systems.
- Targeting tumors systemically without affecting healthy tissues remains an unmet challenge in the field.
- Further innovation is required to create gene therapy vectors that can efficiently reach and treat both primary and metastatic cancers.
Related Concept Videos
00:59Gene Therapy
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:29Microorganisms in Medicine and Therapeutics
01:16In-vitro Mutagenesis
02:15Experimental RNAi